Finlands Akademi  
 
 
 
 
 
Finansieringsbeslut
 
Sökande / Kontakt person Häkkinen, Suvi
Organisation Teknologiska forskningscentralen VTT Ab
Projektets titel Genome editing and metabolic engineering of alkaloid biosynthesis in plants (GEMPlant)
Beslutnr 330128
Beslutsdatum 27.05.2020
Finansierings period 01.09.2020 - 31.08.2024
Finansiering 543 241
   
Beskrivning av projektet
In the current study, our aim is, for the first time, to apply CRISPR/Cas9 genome editing technology together with recently developed synthetic expression system (SES) for the regulation of alkaloid biosynthesis in plant sources, with the aim of establishment of biotechnological production system for target compounds scopolamine and anatabine. Scopolamine is a high-value anti-cholinergic drug which is currently extracted from cultivated plants. Anatabine, on the other hand is a novel drug lead currently actively investigated for various targets, e.g. neurological disorders. In this research, the aim is to use plant cell culture systems in an efficient and sustainable manner to provide high-value natural compounds. The knowhow created within this research will provide completely new concepts within plant metabolic engineering in diverse applications.